ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Parasite and Host
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1658336
This article is part of the Research TopicParasite-Induced Liver Diseases Volume IIView all 5 articles
Oxymatrine alleviates Echinococcus multilocularis infection by remodeling the liver immune microenvironment and intestinal flora homeostasis
Provisionally accepted- 1Ningxia Medical University, Yinchuan, China
- 2General Hospital of Ningxia Medical University, Yinchuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Alveolar echinococcosis (AE) is a zoonotic parasitic disease that poses a grave threat to human health. Oxymatrine has been demonstrated in research studies to regulate gut microbiota, thus treating various diseases, including rheumatoid arthritis and autoimmune encephalomyelitis. Nevertheless, the role of the aforementioned organism in alveolar echinococcosis remains to be elucidated. Methods: This study evaluated the effects of oxymatrine (OMT) at concentrations of 0.25 mM, 0.35 mM, 0.75 mM, 1 mM, and 1.25 mM on Echinococcus multilocularis protoscoleces in vitro over 48 hours, with cell viability assessed using the CCK-8 assay. Subsequently, an E. multilocularis infection model was established by intraperitoneal injection in mice. After three months of infection, the mice were treated daily with intraperitoneal injections of OMT at doses of 25 mg/kg, 50 mg/kg, or 100 mg/kg, alongside albendazole as a reference treatment, for two months. Fecal samples from each group were collected for 16S rRNA sequencing. Following treatment, tissue samples were analyzed. The liver and spleen indices were calculated by measuring mouse body weight, cyst weight, liver weight, and spleen weight. Hepatic pathological changes were examined using hematoxylin-eosin (H&E) and Masson ' s trichrome staining. Additionally, flow cytometry was performed to quantify changes in hepatic CD4+ T cells, CD8+ T cells, and B cells. Results: In vitro experimental results demonstrated that treatment with oxymatrine significantly reduced the viability of Echinococcus multilocularis protoscoleces compared to the control group. The in vivo experimental results demonstrated that, compared with the control group, the 25 mg/kg, 50 mg/kg, and 100 mg/kg OMT-treated groups exhibited significantly reduced cyst weights, marked alleviation of liver inflammatory cell infiltration and fibrosis, and a significant increase in the number of hepatic CD8+ T cells. Furthermore, the 16S rRNA sequencing analysis revealed that OMT intervention enhanced the diversity of gut microbiota. Conclusion: Our data indicate that matrine can directly inhibit the growth of Echinococcus multilocularis in vitro, In vivo studies have shown that three months after infection, matrine can exert an anti-infection effect in the middle and late stages of alveolar echinococcosis by increasing the diversity of intestinal microbiota and the number of CD8+ T cells.
Keywords: OMT, Echinococcus multilocularis, 16S rRNA sequencing, liver immune microenvironment, Alveolar echinococcosis
Received: 02 Jul 2025; Accepted: 18 Sep 2025.
Copyright: © 2025 Zhu, Wu, Wen, Tang, Hou, Yuan, Li, Li and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yazhou Zhu, zhuyazhou188@163.com
Ming Li, nyfygdwk@163.com
Wei Zhao, zw-6915@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.